April 27, 2018

Sydney, Australia, April 27th, 2018 – MEDISCA Australia, a leader in the compounding pharmaceutical industry, is pleased to announce that they had a successful cGMP inspection by the Therapeutic Goods Administration (TGA). The TGA issued an A1 compliant rating of the facility. This is a demonstration of its excellent Quality Management System and continuous efforts in meeting regulatory requirements.   

MEDISCA Australia strives to continuously increase the standard of quality of its products and is dedicated to achieving the highest level of compliance. This achievement is yet another example of MEDISCA Australia staying true to its vision to be the global standard bearer for quality, innovation and service in the compounding industry.


MEDISCA is the leader in providing turnkey solutions to the pharmaceutical compounding industry and allied health care professionals worldwide. Through its global partners, LP3 Network and MEDISCA Network, MEDISCA is committed to being a complete resource for prescribers, pharmacists and pharmacy technicians engaged in personalized medicine by offering educational trainings, products, and support. Founded in 1989, the company has locations in Canada, the United States and Australia, optimizing its service to the international market. For more information about MEDISCA, please visit and follow us on Twitter at @medisca.

Andrew Harb
General Manager - MEDISCA Australia

Toll Free: 1300 786 392


We have placed cookies on your device to help make this website better.

We also use cookies to collect information for making reports and to help us improve the site. The cookies collect information in an anonymous form.

Copyright® 1986-2019 Medisca Inc.
All rights reserved

MEDISCA is ISO 9001:2008 certified